What Testosterone Does for Women's Sexual Function — and What It Doesn't

A 2019 systematic review pooled 36 randomised controlled trials covering 8,480 women and measured what testosterone does across sexual function, cardiometabolic variables, cognition and musculoskeletal health. It found consistent, statistically significant improvements across every sexual-function domain measured in postmenopausal women — and concluded that the effects on individual wellbeing, musculoskeletal and cognitive health, and long-term safety all warrant further investigation.[1]

That asymmetry is the whole picture. One domain is well evidenced. The rest is not.

What the meta-analysis measured

• Design: systematic review and meta-analysis of blinded randomised controlled trials of at least 12 weeks' duration, completed between 1 January 1990 and 10 December 2018.
• Sources: MEDLINE, Embase, the Cochrane Central Register, Web of Science — plus drug registration applications to the European Medicines Agency and the FDA, searched to capture unpublished data.
• Yield: 46 reports of 36 randomised controlled trials, 8,480 participants.
• Comparators: placebo or an active comparator such as oestrogen, with or without a progestogen.
• Registration: PROSPERO CRD42018104073.

Searching regulatory submissions matters more than it sounds. Trials that never reach a journal skew systematically towards null or unfavourable results, and going to the agencies is how a meta-analysis limits that bias.

What it found for sexual function

In postmenopausal women, compared with placebo or comparator:[1]

Outcome	Effect
Satisfactory sexual event frequency	mean difference 0.85 (95% CI 0.52–1.18)
Sexual desire	SMD 0.36 (0.22–0.50)
Pleasure	mean difference 6.86 (5.19–8.52)
Arousal	SMD 0.28 (0.21–0.35)
Orgasm	SMD 0.25 (0.18–0.32)
Responsiveness	SMD 0.28 (0.21–0.35)
Self-image	mean difference 5.64 (4.03–7.26)
Sexual concerns	mean difference 8.99 (6.90–11.08)
Sexual distress	SMD −0.27 (−0.36 to −0.17)

Every interval excludes no-effect. The standardised mean differences sit in the 0.25–0.36 range — by convention, small effects, consistently found. That is a fair characterisation: reliable, measurable, and not transformative.

The most concrete number is the first. Roughly 0.85 additional satisfying sexual events per month is what the pooled trials support. Women considering treatment deserve that figure rather than an adjective.

The lipid finding, and why it decides the route

The meta-analysis also found that testosterone administration produced a significant rise in LDL cholesterol, with reductions in total cholesterol, HDL cholesterol and triglycerides.[1]

That effect is driven by oral administration, and it is the reason the authors' interpretation specifies delivery: testosterone is effective for postmenopausal women with low sexual desire causing distress, with administration via non-oral routes — for example transdermal application — preferred because of a neutral lipid profile.[1]

Route is not a convenience question here. It is part of the recommendation.

What the global consensus says

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women is endorsed by eleven bodies including the International Menopause Society, The Endocrine Society, the International Society for the Study of Women's Sexual Health, and The North American Menopause Society — an unusually broad agreement in a contested area.[2]

Its position is narrow by design: the evidence supports one indication — hypoactive sexual desire dysfunction in postmenopausal women — and does not support treating anything else with testosterone in women.

What is not established

1. Everything other than sexual function. The meta-analysis explicitly flags individual wellbeing, musculoskeletal health and cognitive health as warranting further investigation. Testosterone is not evidence-based for energy, mood, bone or cognition in women.
2. Long-term safety. Trials of 12 weeks and upward do not answer what happens over years.
3. Premenopausal women. The findings are in postmenopausal women; the consensus statement's supported indication is likewise postmenopausal.
4. There is still no approved product for women in most markets, which means dosing is achieved by adapting male preparations — an approach that carries its own risk of overshooting, since female dosing is not male dosing divided down.

The broader clinical framing, including what a woman should ask before starting, is in testosterone therapy for women.

Bottom line

Across 36 randomised trials and 8,480 women, testosterone produced small but consistent and statistically significant improvements in every measured domain of sexual function, and reduced sexual distress — roughly 0.85 more satisfying sexual events per month. It raised LDL cholesterol, which is why non-oral routes are preferred. For every other proposed benefit in women, the honest answer is that the trials have not established it.

References

2 sources

1. Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5 · PMID 31353194
2. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603 · PMID 31498871